For research teamsHelp me find a study
Back to all studies
Not Yet RecruitingNCT07478744

Safety study of SYT-510 in anxiety

This study is not yet recruiting in Global. It is testing SYT-510 for anxiety.

AnxietyDrugFrom 18 Years to 55 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT07478744. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether SYT-510 may be useful for adults experiencing anxiety.

What would participation involve?

Participants may receive SYT-510, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group.

Who is it mainly for?

This study appears to be mainly for adults with anxiety.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The official record does not clearly spell out the visit format, but it appears to be coordinated directly by the research team. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results and safety concerns that need urgent care first. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateEstimated: April 2026
Recruitment status
Not Yet Recruiting
Estimated enrollment
Not clearly listed
Sponsor
Synendos Therapeutics AG
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
Global
Age range
From 18 Years to 55 Years
Official registry ID
NCT07478744
Official title
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT07478744. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with anxiety. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Do I need to want to stop or reduce tobacco use to participate?

The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Synendos Therapeutics AG, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.